CLINICAL_TRIALS
trial_result
· 2020-01-13
Clinical Trial Update: Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder [Phase 3]
Summary
Phase 3 relapse-prevention study of levomilnacipran ER in adults with major depressive disorder completed; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Forest Laboratories | Conditions: Depression, Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2020-01-13